ConductScience.org, home

Paper39508562

Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study.

Ishii T and 7 others. Mod Rheumatol, 2025. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study. Papers, record 39508562. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39508562

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study.
PubMed
Journal
Mod Rheumatol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Observational Study
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
4.55, provisional
iCite
Revised in PubMed
2025-04-14
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ishii TTomonori
2Kunishige HHideaki
3Kobayashi TTamami
4Hayashi EEtsuko
5Komatsubara MMasaki
6Alfonso-Cristancho RRafael
7Tamaoki JJun
8Howarth PPeter

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Granulomatosis with PolyangiitisMajor topic
Humans
Female
Male
Middle Aged
Japan
Treatment Outcome
Aged
Adult

Source PubMed

Download CSV of topics

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
42765531Early mepolizumab initiation during remission induction is associated with lower organ damage burden in EGPA: a multicentre cohort study.Rheumatology (Oxford)2026https://conductscience.org/library/papers/42765531PubMed
42657158
Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study.
Front Allergy2026https://conductscience.org/library/papers/42657158PubMed
42552373Advances in the treatment of eosinophilic granulomatosis with polyangiitis.Nat Rev Rheumatol2026https://conductscience.org/library/papers/42552373PubMed
42324522Mepolizumab initiation by day 30 and glucocorticoid exposure in newly diagnosed EGPA: a single-center 30-day landmark cohort study.BMC Pulm Med2026https://conductscience.org/library/papers/42324522PubMed
42279601Diagnosis and Treatment Pathway for Eosinophilic Granulomatosis with Polyangiitis in the Allergy Department.Diagnostics (Basel)2026https://conductscience.org/library/papers/42279601PubMed
42100060Real-World Effectiveness of MEpolizuMaB in Eosinophilic Granulomatosis with Polyangiitis in Greece: A Protocol for a Multicentre Retrospective Observational Study - The MEMBER Study.Mediterr J Rheumatol2026https://conductscience.org/library/papers/42100060PubMed
42095000Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES.J Allergy Clin Immunol Glob2026https://conductscience.org/library/papers/42095000PubMed
42051495Expert review and recommendations on the diagnosis and therapeutic management of eosinophilic granulomatosis with polyangiitis.Front Immunol2026https://conductscience.org/library/papers/42051495PubMed
41574554Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice.Allergy2026https://conductscience.org/library/papers/41574554PubMed
40566054
High Disease Burden and Oral Corticosteroid Use in Patients with Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis: Country-Level Insights into Real-World Management in Europe.
J Clin Med2025https://conductscience.org/library/papers/40566054PubMed
40305320Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies.Biomolecules2025https://conductscience.org/library/papers/40305320PubMed
40100113Efficacy and safety of mepolizumab in eosinophilic granulomatosis with polyangiitis: Insights from real-life cases and literature analysis.Sarcoidosis Vasc Diffuse Lung Dis2025https://conductscience.org/library/papers/40100113PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39508562

GET https://conductscience.org/api/papers/v1/39508562/authors